Approve in one pass, not five.
Every claim, reference, and safety statement checked upfront, so content reaches MLR ready to approve.
Science moves faster than approvals.
Substantiating by hand
takes hours per asset.
Each claim matched to its reference, line by line against the source, for every asset in the queue.
Every change starts
another cycle.
Medical, legal, and regulatory each take their pass, and any change sends it back through again. Days become weeks.
One campaign, tailored
market by market.
Labels, local codes, allowed channels, and reference formats all differ, and each market’s version has to be checked on its own terms.
Meaningful oversight, before MLR and after.
Blee is an AI marketing compliance platform built for life sciences. Each claim is matched to its reference and each market's current rules, before MLR and after launch, so nothing reaches your experts unchecked.
The source itself,
not a score.
Each claim shown beside the exact supporting passage from your approved references, so reviewers see the evidence, not a black box.
Fewer rounds,
cleaner drafts.
The routine issues are caught before review, so your reviewers start from a cleaner draft.
An early signal for
every market.
One asset checked against all its target markets at once—FDA, national requirements, local codes—so reviewers see early what each market needs.
Fits your review stack, doesn’t replace it
Your frameworks, your labels, ready from day one.
Your markets’ regulations are ready from day one, with your own guidelines, approved claims, and labels layered on top.
United States
FDA promotional rules and FTC advertising requirements.
Europe, UK, & International
National authorities and self-regulatory bodies market by market, from the ABPI/PMCPA in the UK to Germany, France, Italy, and Spain across the EU, and key APAC markets like Singapore.
Approved-claims library
Your substantiated claims, with expiry dates flagged before they lapse.
Local reference rules
Citation and reference formats per market, down to Vancouver style where required.
Claims within the label
Claims stay inside the approved indication, so “supports diagnosis” doesn’t become “makes diagnosis.” For devices, bounded by the current IFU.
Don't see your regulation or market here?
It comes in the same way.
Built for industry leaders
Manage your marketing content like the world's most trusted brands.
"We're partnering with Blee to integrate their AI platform into our workflow, which will empower our teams to move faster and more efficiently, without compromising on the trust and transparency our customers expect."
“Trust is at the core of Greenlight, and Blee helps us scale that trust responsibly in our marketing. Clear processes and guardrails allow our teams to deliver consistent, accurate, and useful messages to the families we serve.”
"With Blee as our compliance partner for marketing reviews, we’re able to share new programs fast—and stay true to the standards that matter."
FAQ
Yes, always. Blee runs the first pass and surfaces what needs attention, but every approval stays with your reviewers—medical for balance, legal for defensibility, regulatory for what’s approved and filed. The system supports their judgment; it does not replace it.
Each claim is matched to the supporting reference you’ve approved, and the exact passage is shown beside the claim, so a reviewer sees the source, not just a match score. Substantiate a claim once, and it carries forward the next time it appears, in any wording.
Yes. Blee checks that claims stay within the approved indication—“supports diagnosis” rather than “makes diagnosis.” For devices, claims are bounded by the current IFU, and checks follow the current version.
Yes. Each market’s national requirements, local codes, and reference formats are applied per asset, so a claim checked for the US is also checked against the rules of the UK, Germany, or wherever it’s headed, down to details like the citation format a market requires.
Yes. Whether it’s one asset or hundreds of near-identical variations from an agency, each is checked against your current guidelines automatically, so volume doesn’t mean a backlog or inconsistent review.
